Merck: new positive data on Keytruda
(CercleFinance.com) - Merck has unveiled new positive data on one of its flagship drugs, the anti-PD1 Keytruda (pembrolizumab) therapy at the annual conference of the American Society of Clinical Oncology (ASCO).
In the Phase II Keynote-158 study, which evaluates the product as monotherapy in patients with previously treated small-cell lung cancer, interim data showed an overall response rate of 18.7%, the primary endpoint of the study.
Furthermore, Keytruda has demonstrated a benefit in terms of long-term survival after four and five years of monitoring, in two pivotal studies evaluating the product in advanced melanoma (Phase III Keynote-006 and Phase Ib Keynote-001 studies).
Copyright (c) 2018 CercleFinance.com. All rights reserved.
In the Phase II Keynote-158 study, which evaluates the product as monotherapy in patients with previously treated small-cell lung cancer, interim data showed an overall response rate of 18.7%, the primary endpoint of the study.
Furthermore, Keytruda has demonstrated a benefit in terms of long-term survival after four and five years of monitoring, in two pivotal studies evaluating the product in advanced melanoma (Phase III Keynote-006 and Phase Ib Keynote-001 studies).
Copyright (c) 2018 CercleFinance.com. All rights reserved.